| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2015184405 |
| Title |
Aromatic Compounds, Compositions and Uses Thereof. |
| Abstract |
Aromatic compounds that are bromodomain inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions comprising an aromatic compound as detailed herein are provided, as are kits comprising a compound or a salt thereof and instructions for use, e.g., in a method of treating cancer. |
| Applicant(s) |
Medivation Technologies, Inc |
| Representative Drug(s) |
D03RPJ |
Drug Info
|
IC50 = 220 nM |
Click to Show More |
[1] |
|
2
|
D03NWT
|
Drug Info
|
N.A.
|
[1] |
|
3
|
D05XXS
|
Drug Info
|
N.A.
|
[1] |
|
4
|
D0NN4U
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2015075665 |
| Title |
Pyrrolopyrrolone Derivatives and Their Use As Bet Inhibitors. |
| Abstract |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. |
| Applicant(s) |
Novartis Ag |
| Representative Drug(s) |
D0YM3G |
Drug Info
|
IC50 < 11 nM |
[1] |
| Patent ID |
WO2015018523 |
| Title |
A Novel Bet-Brd Inhibitor for Treatment of Solid Tumors. |
| Abstract |
A method of treating a solid in a mammal comprising the step of: administering a pharmaceutical acceptable amount of a thienotriazolodiazepine compound being represented by the following Formula (1): wherein R1 is alkyl having a carbon number of 1-4, R2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R3 is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1 -4, alkoxy having a carbon number of 1-4 or cyano;...NR5...(CH2)m...R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R6 is phenyl or pyridyl optionally substituted by a halogen atom; or -NR 7...CO...(CH2)n...R8 wherein R7 is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R8 is phenyl or pyridyl optionally substituted by a halogen atom, and R4 is ...(CH2)a...CO...NH...R9 wherein a is an integer of 1-4, and R9 is alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or...(CH2)b...COOR10 wherein b is an integer of 1-4, and R10 is alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof. |
| Applicant(s) |
Oncoethix Gmbh |
